阿利西尤单抗治疗急性冠脉综合征的成本效益:ODYSSEY OUTCOMES试验
基于ODYSSEY OUTCOMES试验18,924例近期急性冠脉综合征且已接受优化他汀治疗患者的个体数据,构建终身成本效益模型。阿利西尤单抗相比安慰剂,总体增量成本效益比为每QALY 92,200美元;基线LDL-C≥100 mg/dl者每QALY 41,800美元,<100 mg/dl者每QALY 299,400美元。
要点
- 近期ACS且优化他汀治疗患者,阿利西尤单抗总体ICER为每QALY 92,200美元。
- 基线LDL-C≥100 mg/dl者ICER为每QALY 41,800美元,具良好经济价值。
- 基线LDL-C<100 mg/dl者ICER为每QALY 299,400美元,经济价值较低。
核心结论
- 在近期急性冠脉综合征且接受优化他汀治疗的患者中,阿利西尤单抗改善心血管结局,成本效益为中等价值。
- 基线LDL-C≥100 mg/dl患者具有良好经济价值,而LDL-C<100 mg/dl患者经济价值较低。
研究设计与样本
- 基于ODYSSEY OUTCOMES试验患者水平数据的成本效益模型,估计终身 horizon 的成本与结局。
- 纳入18,924例近期急性冠脉综合征患者,均接受高强度或最大耐受剂量他汀治疗。
- 患者基线LDL-C≥70 mg/dl、非高密度脂蛋白胆固醇≥100 mg/dl或载脂蛋白B≥80 mg/l。
- 阿利西尤单抗75 mg或安慰剂每2周皮下注射,LDL-C仍≥50 mg/dl时盲法滴定至150 mg,连续两次LDL-C<15 mg/dl则换回安慰剂。
- 计算增量成本每质量调整生命年(QALY),并按基线LDL-C≥100 mg/dl和<100 mg/dl分层。
主要发现
- 总体人群年治疗成本5,850美元时,平均总体增量成本效益比为每QALY 92,200美元(基础案例)。
- 基线LDL-C≥100 mg/dl患者每QALY成本为41,800美元。
- 基线LDL-C<100 mg/dl患者每QALY成本为299,400美元。
- 在LDL-C≥100 mg/dl患者中,多种敏感性分析下增量成本效益比均低于每QALY 100,000美元。
临床怎么用
- 对于近期急性冠脉综合征且优化他汀治疗后基线LDL-C≥100 mg/dl的患者,加用阿利西尤单抗具有良好经济价值。
- 基线LDL-C<100 mg/dl患者加用阿利西尤单抗的经济价值较低,决策时需结合成本考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cholesterol reduction with proprotein convertase subtilisin-kexin type 9 inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients with recent acute coronary syndrome remains uncertain. OBJECTIVES: This study sought to determine whether further cholesterol reduction with alirocumab would be cost-effective in patients with a recent acute coronary syndrome on optimal statin therapy. METHODS: A cost-effectiveness model leveraging patient-level data from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was developed to estimate costs and outcomes over a lifetime horizon. Patients (n = 18,924) had a recent acute coronary syndrome and were on high-intensity or maximum-tolerated statin therapy, with a baseline low-density lipoprotein cholesterol (LDL-C) level ≥70 mg/dl, non-high-density lipoprotein cholesterol ≥100 mg/dl, or apolipoprotein B ≥80 mg/l. Alirocumab 75 mg or placebo was administered subcutaneously every 2 weeks. Alirocumab was blindly titrated to 150 mg if LDL-C remained ≥50 mg/dl or switched to placebo if 2 consecutive LDL-C levels were <15 mg/dl. Incremental cost per quality-adjusted life-year (QALY) was determined with the addition of alirocumab versus placebo and, based on clinical efficacy findings from the trial, was stratified by baseline LDL-C levels ≥100 mg/dl and <100 mg/dl. RESULTS: Across the overall population recruited to the ODYSSEY OUTCOMES trial, using an annual treatment cost of US$5,850, the mean overall incremental cost-effectiveness ratio was US$92,200 per QALY (base case). The cost was US$41,800 per QALY in patients with baseline LDL-C ≥100 mg/dl, whereas in those with LDL-C <100 mg/dl the cost per QALY was US$299,400. Among patients with LDL-C ≥100 mg/dl, incremental cost-effectiveness ratios remained below US$100,000 per QALY across a wide variety of sensitivity analyses. CONCLUSIONS: In patients with a recent acute coronary syndrome on optimal statin therapy, alirocumab improves cardiovascular outcomes at costs considered intermediate value, with good value in patients with baseline LDL-C ≥100 mg/dl but less economic value with LDL-C <100 mg/dl. (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]; NCT01663402).
引用
- Bhatt DL, Briggs AH, Reed SD, et al. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020. PMID: 32381160. doi:10.1016/j.jacc.2020.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。